Moderna. mRNA. Vaccines. With those three words, I’ve probably already lost a few of you, who by now are probably readying your pitchforks, torches, and angry emojis.
But for those of you who are still with me, I’d like to offer a few of my thoughts on Moderna’s recent announcement on the efficacy of a personalized mRNA vaccine – in combination with traditional immunotherapy – in treating patients with stage III/IV melanoma.
|
|
